Shots:

• The submission is based on the P-III MOVe-OUT trial that evaluates molnupiravir (800mg- bid) in non-hospitalized adult patients with COVID-19
• At the interim analysis- the therapy showed a ~50% reduction in risk of hospitalization or death; patients were hospitalized (7.3% vs 14.1%) through 29Day following randomization- no deaths were reported in patients who received molnupiravir
• If EC grants Marketing Authorization- Molnupiravir will be the 1st antiviral therapy to treat COVID-19 in the EU. On Oct 11- 2021- Merck had submitted an application for EUA to the US FDA for molnupiravir while additional submissions to regulatory agencies globally are ongoing

 ­ Ref: Merck | Image: Merck